<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873338</url>
  </required_header>
  <id_info>
    <org_study_id>CNTX-CX-01-2015-AML-1</org_study_id>
    <nct_id>NCT02873338</nct_id>
  </id_info>
  <brief_title>Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CX-01 when given together with standard
      induction and consolidation therapy for acute myeloid leukemia (AML) will increase the
      effectiveness of the induction/consolidation therapy. Two different doses of CX-01 will be
      studied and safety and tolerability will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized open-label study is designed to evaluate whether the addition of either or
      both different dose levels of CX-01 to standard induction therapy and consolidation therapy
      has a beneficial effect in newly diagnosed AML patients (60 years of age or older) when
      compared to patients receiving standard induction and consolidation chemotherapy alone. 75
      patients will be randomized to one of 3 treatment groups to receive standard
      induction/consolidation therapy alone or standard induction/consolidation therapy with CX-01
      at one of 2 different dose levels (lower and higher). Patients will receive up to 2 induction
      cycles and up to 2 consolidation cycles and will participate in the study for up to 18
      months. Clinical laboratory tests will be conducted routinely, and bone marrow aspirates and
      biopsies will be performed during the induction cycles. Safety will be monitored through
      adverse events and clinical laboratory results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphologic complete remission evaluated by IWG criteria (ANC &gt;1000/microliter; platelet count &gt;100,000, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, no evidence of extramedullary disease</measure>
    <time_frame>during induction and re-induction phases of treatment (up to 60 days after the start of each treatment cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (length of time from randomization through treatment failure)</measure>
    <time_frame>every 3 months continuing until death or until 18 months after the last patient is randomized (whichever comes first)</time_frame>
    <description>Treatment failure: failure to achieve composite complete morphological remission during the induction and re-induction phase of the study lasting up to 60 days, relapse from complete response or death from any cause, whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival (length of time from the date of randomization until disease relapse or patient death from any cause, whichever comes first, in patients who achieve complete remission only)</measure>
    <time_frame>every 3 months continuing until death or until 18 months after the last patient is randomized (whichever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (length of time from the date of randomization until death from any cause)</measure>
    <time_frame>every 3 months continuing until death or until 18 months after the last patient is randomized (whichever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite complete remission rate (complete remission + complete remission with incomplete blood count recovery)</measure>
    <time_frame>during induction and re-induction phases of treatment (up to 60 days after the start of each treatment cycle)</time_frame>
    <description>Complete remission: ANC &gt;1000/microliter, platelet count &gt;100,000, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, no evidence of extramedullary disease
Complete remission with incomplete blood count recovery: ANC &lt;1000/microliter and/or platelet count &lt;100,000, &lt;5% blasts in bone marrow aspirate, no blasts with Auer rods, no evidence of extramedullary disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of morphologic complete remission (time from the achievement of complete response to the detection of relapse)</measure>
    <time_frame>every 3 months continuing until death or until 18 months after the last patient is randomized (whichever comes first)</time_frame>
    <description>Relapse: reappearance of leukemia blasts in the peripheral blood; or &gt;5% blasts in the bone marrow not attributable to another cause; or appearance or reappearance of extramedullary disease and the bone marrow blast percentage is &gt;5% but &lt; or equal to 20%, than a repeat bone marrow performed at least 7 days after the first marrow examination and documenting bone marrow blast percentage is &gt;5% is necessary to establish relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil recovery - Time from date of randomization to ANC recovery (ANC &gt; 1000/microliter)</measure>
    <time_frame>up to 60 days after the start of each treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet recovery - Time from date of randomization to platelet recovery (platelet count &gt;100,000/microliter)</measure>
    <time_frame>up to 60 days after the start of each treatment cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality (rate of death)</measure>
    <time_frame>30 days from the first day of induction treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60-day mortality (rate of death)</measure>
    <time_frame>60 days from the first day of induction treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality (rate of death)</measure>
    <time_frame>90 days from the first day of induction treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Idarubicin + Cytarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction:
Idarubicin - 12 mg/m2/day slow IV injection for 3 days;
Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 7 days
Re-induction - same as above or:
Idarubicin - 12 mg/m2/day slow IV injection for 2 days;
Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days
Consolidation:
Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idarubicin+Cytarabine+lower dose CX-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:
Idarubicin - 12 mg/m2/day slow IV injection for 3 days;
Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 7 days;
CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 7 days
Re-induction - same as above or:
Idarubicin - 12 mg/m2/day slow IV injection for 2 days;
Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days
CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 5 days
Consolidation:
Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days
CX-01 - 4 mg/kg IV bolus followed by CX-01 0.125 mg/kg/hr as a continuous 24-hour IV infusion for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idarubicin+Cytarabine+higher dose CX-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:
Idarubicin: 12 mg/m2/day slow IV injection for 3 days;
Cytarabine: 100 mg/m2/day continuous 24-hour IV infusion for 7 days;
CX-01: 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 7 days
Re-Induction - same as above or:
Idarubicin - 12 mg/m2/day slow IV injection for 2 days;
Cytarabine - 100 mg/m2/day continuous 24-hour IV infusion for 5 days;
CX-01 - 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 5 days
Consolidation:
Cytarabine - 1.0 g/m2 IV infusion over 3 hours, q12h every other day for 3 days
CX-01 - 4 mg/kg IV bolus followed by CX-01 0.25 mg/kg/hr as a continuous 24-hour IV infusion for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-01</intervention_name>
    <description>4 mg/kg IV bolus followed by doses of 0.125, or 0.25 mg/kg/hr given on days 1 through 7 with standard induction therapy, on days 1 through 5 or 7 with standard re-induction therapy, and on days 1, 3 and 5 with standard consolidation therapy</description>
    <arm_group_label>Idarubicin+Cytarabine+lower dose CX-01</arm_group_label>
    <arm_group_label>Idarubicin+Cytarabine+higher dose CX-01</arm_group_label>
    <other_name>2-O, 3-O desulfated heparin</other_name>
    <other_name>ODSH</other_name>
    <other_name>PGX-100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>12 mg/m2/day by slow (10 to 15 minutes) IV injection daily on days 1, 2 and 3 of induction therapy, and on days 1 and 2 of re-induction therapy</description>
    <arm_group_label>Idarubicin + Cytarabine</arm_group_label>
    <arm_group_label>Idarubicin+Cytarabine+lower dose CX-01</arm_group_label>
    <arm_group_label>Idarubicin+Cytarabine+higher dose CX-01</arm_group_label>
    <other_name>Idamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg/m2/day by continuous IV infusion on days 1 through 7 of induction therapy, and on days 1 through 5 of re-induction therapy
1.0 g/m2 IV infusion given over 3 hours every 12 hours on days 1, 3, and 5 of consolidation therapy</description>
    <arm_group_label>Idarubicin + Cytarabine</arm_group_label>
    <arm_group_label>Idarubicin+Cytarabine+lower dose CX-01</arm_group_label>
    <arm_group_label>Idarubicin+Cytarabine+higher dose CX-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, de novo or secondary, previously untreated AML

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Prior chemotherapy for AML

          -  Prior intensive chemotherapy or stem cell transplantation for the treatment of
             myelodysplastic syndrome

          -  CNS leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Marcus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cantex Pharmaceuticals. Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Marcus, MD</last_name>
    <phone>954-315-3660</phone>
    <email>smarcus@cantex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Balandis, PharmD</last_name>
    <phone>954-315-3660</phone>
    <email>sbalandis@cantex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego, Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wieduwilt, MD</last_name>
      <phone>858-822-5354</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Maris, MD</last_name>
      <phone>720-754-4800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imaduddin Tabbarah, MD</last_name>
      <phone>202-741-2478</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen E Rubenstein, MD</last_name>
      <phone>317-859-5252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>June E. Nylen Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald B Wender, MD</last_name>
    </contact>
    <contact_backup>
      <phone>(712) 252-0088</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Stevens, MD</last_name>
      <phone>502-899-3366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University/Tulane Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hana Safah, MD</last_name>
      <phone>504-988-6300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Yang, MD</last_name>
      <phone>313-576-8952</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allina Health - Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Tsai, MD</last_name>
      <phone>612-884-6300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Westervelt, MD</last_name>
      <phone>314-454-8365</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Arana-Yi, MD</last_name>
      <phone>505-272-4946</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Mantzaris, MD</last_name>
      <phone>718-920-4826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Kolitz, MD</last_name>
      <phone>516-734-8970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zartash Gul, MD</last_name>
      <phone>513-584-7661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Cook, MD</last_name>
      <phone>503-494-9630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Reagan, MD</last_name>
      <phone>401-444-5435</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Stuart, MD</last_name>
      <phone>843-792-9300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod Parameswaran, MD</last_name>
      <phone>605-322-3086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William B Donnellan, MD</last_name>
      <phone>615-329-5090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Levy, MD</last_name>
      <phone>214-370-1065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose C Cruz, MD</last_name>
      <phone>210-575-6904</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Shami, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daanish Hoda, MD</last_name>
      <phone>801-408-3729</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

